Organización Médica de Investigación (OMI)
Organización Médica de Investigación (OMI)
Uruguay 725 PB , Buenos Aires, CP: 1015
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Ana Malvar
Daniel Politis
Margarita Alfie
Karen Daniela Román
Open studies
Breast Cancer
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer - EvoPAR-BR01 - AstraZenecaSee more
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence - ELEGANT - Stemline Therapeutics, Inc.See more
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) - TROPION-Breast05 - AstraZenecaSee more
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. - PfizerSee more
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer - ReDiscover-2 - Relay Therapeutics, Inc.See more
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) - PIKALO-2 - Eli Lilly and CompanySee more
Glomerulonephritis
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB - ACTION3 - Dimerix Bioscience Pty LtdSee more
Alzheimer disease
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) - ADEPT-4 - Karuna TherapeuticsSee more
Cardiovascular disease
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) - ATTAIN-Outcomes - Eli Lilly and CompanySee more
Renal disease
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) - ATTAIN-Outcomes - Eli Lilly and CompanySee more
Neuroendocrine neoplasm
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy - DAREON®-NEC-1 - Boehringer IngelheimSee more
